J Bacteriol Virol.  2016 Sep;46(3):152-158. 10.4167/jbv.2016.46.3.152.

Differences in Hematological Characteristics, Including Cholesterol and Apolipoprotein B and E, between Hepatitis B Virus and Hepatitis C Virus Patients in Korea

• Jo HJ
• Park GN
• Kim HR
• Kim MJ
• Shin KA
• Hong SB
• Chang KS

• KMID: 2353850
• DOI: http://doi.org/10.4167/jbv.2016.46.3.152

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) chronically cause hepatitis, liver cirrhosis, and hepatocellular carcinoma, and biomarkers related to liver damage are elevated in HBV and HCV patients. However, comparisons of biomarkers between HBV and HCV patients have not previously been reported. The aim of this study was to investigate differences in hematological biomarker in the sera of HBV and HCV patients and to find a key biomarker to differentiate between HBV and HCV infections. HBV (n=115) and HCV (n=128) samples (serum and whole blood) were collected and tested using a biochemical analysis system. The obtained data were analyzed with SPSS 18.0 statistical software. The mean age of the HCV group (60.3±14.1) was much higher than that of the HBV group (51.1±12.4). Male and female rates were 71.3% and 28.7% in the HBV group and 53.9% and 46.1% in the HCV group, respectively (p = 0.005). AST, ALT, and TG values were higher in the HCV group than in the HBV group. Although γ-GTP and LDL levels were higher in the HBV group than in the HCV group, apoB and apoE levels were much higher in HCV group than in HBV group (p < 0.001). There were no significant differences in the other hematological biomarkers between the HBV and HCV groups. In conclusion, HBV rates were higher in male patients, and HCV rates were higher in older patients. In particular, apoE and apoB were more highly expressed in HCV patients, and they might be key markers to differentiate HCV infection.

Keyword

Hepatitis B virus; Hepatitis C virus; Hematological biomarker; Apolipoprotein B & E

MeSH Terms

Apolipoproteins B
Apolipoproteins E
Apolipoproteins*
Biomarkers
Carcinoma, Hepatocellular
Cholesterol*
Female
Hepacivirus*
Hepatitis B virus*
Hepatitis B*
Hepatitis C*
Hepatitis*
Humans
Korea*
Liver
Liver Cirrhosis
Male
Apolipoproteins
Apolipoproteins B
Apolipoproteins E
Biomarkers
Cholesterol

Figure

• 

  Figure 1. Distribution of HBV and HCV patients according to age.

Reference

1). Li HC, Lo SY. Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol. 2015; 7:1377–89.

2). Manzoor S, Saalim M, Imran M, Resham S, Ashraf J. Hepatitis B virus therapy: What's the future holding for us? World J Gastroenterol. 2015; 21:12558–75.

3). Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z. Hepatitis C virus: A global view. World J Hepatol. 2015; 7:2676–80.

4). Hishiki T, Shimizu Y, Tobita R, Sugiyama K, Ogawa K, Funami K, et al. Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J Virol. 2010; 84:12048–57.

5). Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology. 2010; 51:1904–11.

6). Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T. Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding. Hepatology. 2012; 56:484–91.

7). Feitelson M. Hepatitis B virus infection and primary hepatocellular carcinoma. Clin Microbiol Rev. 1992; 5:275–301.

8). Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology. 2009; 49:S56–60.

9). Chang KS, Jiang J, Cai Z, Luo G. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol. 2007; 81:13783–93.

10). André P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, et al. Characterization of lowand very-low-density hepatitis C virus RNA-containing particles. J Virol. 2002; 76:6919–28.

11). André P, Perlemuter G, Budkowska A, Bréchot C, Lotteau V. Hepatitis C virus particles and lipoprotein metabolism. Semin Liver Dis. 2005; 25:93–104.

12). Jiang J, Luo G. Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol. 2009; 83:12680–91.

13). Owen DM, Huang H, Ye J, Gale M Jr. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology. 2009; 394:99–108.

14). Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut. 2010; 59:1279–87.

15). Dueñas-Carrera S. Hepatitis C virus and lipid metabolism: their implications in vaccine development and treatment. Biotecnol Apl. 2011; 28:1–5.

16). Shimizu Y, Hishiki T, Ujino S, Sugiyama K, Funami K, Shimotohno K. Lipoprotein component associated with hepatitis C virus is essential for virus infectivity. Curr Opin Virol. 2011; 1:19–26.

17). Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus, cholesterol and lipoproteins–impact for the viral life cycle and pathogenesis of liver disease. Viruses. 2013; 5:1292–324.

18). Fierro NA, Gonzalez-Aldaco K, Torres-Valadez R, Martinez-Lopez E, Roman S, Panduro A. Immunologic, metabolic and genetic factors in hepatitis C virus infection. World J Gastroenterol. 2014; 20:3443–56.

19). Kim YS, Paeng JR, Woo JT, Kim SW, Yang IM, Kim JW, et al. Apolipoprotein E genotypes of normal and hyperlipidemic subjects. J Korean Med Sci. 1993; 8:262–6.

20). Shin MH, Kim HN, Cui LH, Kweon SS, Park KS, Heo H, et al. The effect of apolipoprotein E polymorphism on lipid levels in Korean adults. J Korean Med Sci. 2005; 20:361–6.

21). Yin Z, Xiong C, Wang Y, Zhou X, Yan SK. Investigation of the relationship between apolipoprotein E gene polymorphisms and hepatitis B virus infection in northern China. Clin Chem Lab Med. 2010; 48:1803–7.

22). Price DA, Bassendine MF, Norris SM, Golding C, Toms GL, Schmid ML, et al. Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. Gut. 2006; 55:715–8.